## **IBD Treatment and COVID-19**

### Rajeev Jain, MD, AGAF

AGA Patient Education Advisor Texas Digestive Disease Consultants

### David T. Rubin, MD, AGAF

Joseph B. Kirsner Professor of Medicine; Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine, Illinois

### Russell D. Cohen, MD, AGAF

Professor of Medicine; Director, Inflammatory Bowel Disease Center University of Chicago Medicine, Illinois



## **British Society of Gastroenterology**



# COVID-19 Guidance and Advice IBD Risk Grid

Highest Risk 'Shielding'	Moderate risk 'Stringent social distancing'	Lowest risk 'Social distancing'		
<ol> <li>IBD patients who either have a comorbidity (respiratory, cardiac, hypertension or diabetes mellitus) and/or are ≥70 years old</li> </ol>	Patients on the following medications:  • Anti-TNF (infliximab, adalimumab, golimumab) monotherapy	Patients on the following medications:  • 5ASA		
and* are on any 'moderate risk' therapy for IBD (per middle column)	Biologic plus immunomodulator** in stable patients     Ustekinumab	Rectal therapies     Orally administered     topically acting steroids     (budesonide or		
2. IBD patients of any age regardless of comorbidity and who meet one or more of the following criteria:  ○ Intravenous or oral steroids ≥20 mg prednisolone or equivalent per day (only while on this dose)  ○ Commencement of biologic plus either immunomodulator or systemic steroids within previous 6 weeks**  ○ Moderate-to-severely active disease*** not controlled by 'moderate risk' treatments  ○ Short gut syndrome requiring nutritional	Vedolizumab Thiopurines (azathioprine, mercaptopurine, tioguanine) Methotrexate Calcineurin inhibitors (tacrolimus or ciclosporin) Janus kinase (JAK) inhibitors (tofacitinib) Immunosuppressive trial medication Mycophenolate mofetil Thalidomide	(budesonide or beclometasone)  Therapies for bile acid diarrhoea (colestyramine, colesevelam, colestipol)  Anti-diarrhoeals (e.g. loperamide)  Antibiotics for bacterial overgrowth or perianal disease		
support o Requirement for parenteral nutrition	Prednisolone <20 mg or equivalent per day			



bsg.org.uk/covid-19-advice. Accessed March 31, 2020.

# What About IBD Therapy? OBD 5



Statement	5-ASA	BUD	PRED ≥20mg/d	AZA/ 6MP	мтх	Anti- TNF	VEDO	UST	TOFA
This therapy increases the risk of infection with SARS-CoV-2.									
This therapy increases the risk of COVID-19.									
Patients taking this therapy should <b>reduce</b> the dose of therapy to prevent SARS-CoV-2 infection.									
Patients taking this therapy should <b>discontinue</b> therapy to prevent SARS-CoV-2 infection.									
Patients taking this therapy should <b>stop</b> therapy if they test positive for SARS-CoV-2 but don't have the COVID-19.									
Patients taking this therapy should <b>stop</b> therapy if they develop COVID-19.									

Appropriate	Uncertain	Inappropriate
-------------	-----------	---------------

## What About IBD Therapy?



	5-ASA	BUD	PRED (≥20mg /d)	AZA/ 6MP	мтх	Anti- TNF	VEDO	UST	TOFA
To <b>prevent</b> SARS-CoV-2 infection.									
If infected with SARS- CoV-2 but don't have COVID-19.									
Confirmed COVID-19.									

O Continue Therapy (

Unsure

Hold/Delay/Stop Therapy

## **Reliable References to Stay Updated**

- who.int/health-topics/coronavirus
- cdc.gov/coronavirus/2019-ncov
- coronavirusupdates.uchicago.edu
- crohnscolitisfoundation.org/coronavirus
- rubinlab.uchicago.edu/blog
- twitter.com/IBDMD
- covidibd.org
- clinicaltrials.gov
- gastro.org/covid









### **RUBIN'S REFLECTIONS**





